The iTind™ Procedure
First-line Treatment for BPH

iTind Treatment

Managing lower urinary tract symptoms in patients with BPH is a delicate juggling act. Rapid symptom relief is very important, but as more aging patients maintain very active lifestyles, preserving this and sexual function are of growing importance to them.* With the iTind procedure, many patients may not have to compromise. The iTind procedure is an alternative to medications and their side effects and is a minimally invasive alternative to surgery.

Learn More About the iTind Procedure

*Bruskewitz RC. Quality of life and sexual function in patients with benign prostatic hyperplasia. Rev Urol. 2003;5(2):72-80.

The American Urological Association (AUA) Clinical Practice Guideline for the iTind™ procedure

The iTind procedure is now included in the American Urological Association (AUA) clinical practice guideline for Management of Lower Urinary Tract Symptoms (LUTS) Attributed to Benign Prostatic Hyperplasia (BPH), also known as enlarged prostate. The iTind procedure is reflected in the new procedure category, Temporary Implanted Prostatic Devices (TIPD).5 The addition of the TIPD category is based on expert opinion reflecting peer-reviewed treatment recommendations and research updates.

Treatment with the iTind procedure is straightforward and provides rapid symptom relief in the majority of patients.1,2,3 The procedure can be performed in an office or outpatient hospital procedure, under general or local anesthesia. Patients typically return home the same day and often do not require a catheter.1 For patients who prefer a non-pharmaceutical approach to treating their BPH symptoms or are not yet ready for surgery, the iTind procedure may be well suited to become a first-line treatment.1

The iTind™ Center of Excellence Program is designed to enhance patient outcomes and experiences.
LEARN MORE

iTind™ CENTER OF EXCELLENCE

Why Choose the iTind™ Procedure?

The iTind Procedure May Be an Ideal Treatment for Men Age 50 and Over Who:
  • Are not happy with medical therapy
  • Are not yet ready for surgery
  • Want to preserve sexual function
  • Do not want a catheter post procedure*

*In published clinical studies, less than 5% of patients required temporary placement of a catheter post-procedure. As with any product, results may vary.

The iTind Procedure May be an Ideal Treatment for Men Age 50 and Over With:1,2
  • Small or medium-sized prostate
  • No obstructive median lobe
  • High or tight bladder neck
  • Good bladder function
Benefits
  • Reshapes the prostate without permanent implants
  • Preserves sexual function1,2
  • Temporary implant, removed after only 5-7 days
  • Rapid symptom relief, rapid return to daily life1,2,3
  • Straightforward procedure with no need for special capital equipment
  • Low incidence of post-op catheterization (~5%)1

Implantation of the iTind device may cause urinary urgency, pelvic discomfort, dysuria or hematuria. In rare cases, the iTind procedure may cause urinary tract infection or acute urinary retention.

Jim, iTInd Procedure Patient
''
It’s been 15 months since the iTind™ procedure. The first time I urinated I was amazed. I felt like I was 16 years old again.”
- Jim, iTind Procedure Patient
  Recorded February 2022
Jim was treated with the iTind procedure and is an unpaid speaker. As with any product, results may vary.

Mechanism of Action

The iTind™ device is placed within the prostatic urethra in a folded configuration. Once in place, the iTind device expands and its struts exert longitudinal force on the prostatic urethra and the bladder neck at the 12, 5 and 7 o’clock positions.

Over the course of 5 to 7 days, through continuous ischemic pressure and subsequent tissue necrosis and scarring, deep longitudinal channels are created through which urine can flow freely.

The elegant design of the iTind device allows for a straightforward procedure using cystoscopy equipment most urologists already own. Unlike other treatment options, no energy or heat is used to treat the prostate, greatly reducing the risk of retrograde ejaculation, erectile dysfunction and urinary incontinence.1,2,3

After 5-7 days, the iTind device is completely removed during an in-office procedure. The newly formed channels continue to provide sustained relief over the long-term as demonstrated in published clinical studies out to 4 years.4

Implantation of the iTind device may cause urinary urgency, pelvic discomfort, dysuria or hematuria. In rare cases, the iTind procedure may cause urinary tract infection or acute urinary retention.

(1)
Insertion
(1)
Treatment Period
(5-7 Days)
(1)
Removal

Join the Conversation

X

Clinical Results and Publications

MT02 - 48+ months (View Abstract)
Temporary implantable nitinol device for benign prostatic hyperplasia-related lower urinary tract symptoms: over 48-month results. Minerva Urology and Nephrology. 2023.

MT03 (View Abstract)
Chughtai et al. The iTind temporarily implanted nitinol device for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: a multicenter, randomized, controlled trial. 2020.

MT06 (View Abstract)
De Nunzio et al. Urinary and sexual function after treatment with temporary implantable nitinol device (iTind) in men with LUTS: 6-month interim results of the MT-06-study. 2020.

Reimbursement Resources

Field Reimbursement Managers (FRMs)

Olympus has specific Field Reimbursement experts who can provide additional reimbursement insight and guidance, as well as a wide range of resources specific to the overall reimbursement process for the iTind™ procedure.

Please consult the FRMs via email at iTindFRM@olympus.com.
Olympus® UNITE

Olympus UNITE for the iTind Procedure Helpline

  • Provides support on general questions related to coding for the iTind procedure
  • Discussions on supporting medical record documentation
  • Review of payer explanation for denied prior authorizations or denied claims

Olympus UNITE for iTind Patient Access Program

For complex or case-specific assistance, customers may opt-in to the Olympus UNITE Program. Under this program, third party Case Managers can assist with payer prior authorizations and appeals.

Contact Olympus UNITE

Olympus is partnered with a third-party administrator

Email: OlympusUNITE@priahealthcare.com

Phone: (877) 205-1533

Fax: (877) 573-5196

Hours: 8:30 am - 5:00 pm
Eastern Time

Read press releases, latest news and download images on our Olympus® Medical Media Center
LEARN MORE

Stay up to Date

Please sign up to receive Olympus marketing emails, including more information on the iTind procedure.

The iTind procedure is intended for the treatment of symptoms due to urinary outflow obstruction secondary to benign prostatic hyperplasia (BPH) in men age 50 and above.

It is important to note that results from the iTind™ procedure may vary and not all patients see benefit from this treatment. Implantation of the iTind device may cause pelvic discomfort, blood in urine, painful or urgent urination. In rare cases, the iTind device may cause urinary tract infection or a sudden difficulty to urinate

As with all medical procedures results may vary. Patients should consult with their physician to determine their course of treatment.

1. Amparore, Daniele, et al. “3-Year Results Following Treatment with the Second Generation of the Temporary Implantable Nitinol Device in Men with Luts Secondary to

Benign Prostatic Obstruction.” Prostate Cancer and Prostatic Diseases, vol. 24, no. 2, 2020, pp. 349–357., https://doi.org/10.1038/s41391-020-00281-5.

2. Chughtai, Bilal, et al. “The ITIND Temporarily Implanted Nitinol Device for the Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia: A

Multicenter, Randomized, Controlled Trial.” Urology, vol. 153, 2021, pp. 270–276., doi:10.1016/j.urology.2020.12.022.

3. De Nunzio, C., Cantiello, F., Fiori, C., Crocerossa, F., Tognoni, P., Amparore, D., Baldassarri, V., Elbers, J. R., Sancha, F. G., & Porpiglia, F. (2020). Urinary and sexual function after treatment with temporary implantable nitinol device (itind) in men with luts: 6-month interim results of the MT-06-study. World Journal of Urology, 39(6), 2037–2042. https://doi.org/10.1007/s00345-020-03418-2

4. Amparore D, De Cillis S, Schulman C, Kadner G, Fiori C, Porpiglia F. Temporary implantable nitinol device for benign prostatic hyperplasia-related lower urinary tract symptoms: over 48-month results. Minerva Urol Nephrol. 2023 Jun 23. doi: 10.23736/S2724-6051.23.05322-3. Epub ahead of print. PMID: 37350585.

5. Sandhu JS, Bixler BR, Dahm P, et al. Management of lower urinary tract symptoms attributed to benign prostatic hyperplasia (BPH): AUA Guideline amendment 2023. J Urol. 2023;10.1097/JU.0000000000003698. https://doi.org/10.1097/JU.0000000000003698